Press Releases
-
Feb 7, 2018
Normalization of biomarker and liver size; stabilization of early cognitive effects suggested in preliminary dataBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it presented interim data from a Phase 1/2 trial for BMN 250, an investigational enzyme replacement therapy using a novel fusion of...
-
Feb 6, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that The WORLDSymposium 2018 awarded Brineura® (cerliponase alfa) the New Treatment Award, which recognizes important achievements in...
-
Feb 5, 2018Oral Presentations to Highlight Results from Studies for the Treatment of Sanfilippo Syndrome Type B, Morquio A Syndrome and CLN2 Disease, a Form of Batten Disease
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in five oral and 15 poster presentations at the 14th Annual WORLDSymposiumTM being held February 5-9,...
-
Jan 24, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Jan 3, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 36th Annual J.P. Morgan Healthcare Conference on
-
Dec 22, 2017Regulatory Review Process Proceeding In-line with Company's Expectations
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the Biologics License...
-
Dec 19, 2017Second Phase 3 Study, GENEr8-2, to Begin at the Start of 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has dosed the first patient in the global GENEr8-1 Phase 3 study with the 6e13 vg/kg dose for valoctocogene roxaparvovec...
-
Dec 11, 2017New 1.5 Year Results Demonstrating 6e13 vg/kg Dose Achieved Sustained Factor VIII Levels within the Normal Range in Severe Hemophilia A for Most Patients
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced updates on valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy treatment for severe hemophilia at ASH. Efficacy...
-
Dec 9, 2017Valoctocogene Roxaparvovec Demonstrated Sustained Normal or Near Normal Factor VIII Levels in Severe Hemophilia A for Most Patients at Both Doses in Phase 1/2 Study
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec (formerly BMN 270), an...
-
Dec 6, 2017Oral Presentation to Include 78 Week Data with 6e13 Dose Cohort and 32 Week Data with 4e13 Dose Cohort from its Ongoing Phase 1/2 valoctocogene roxaparvovec (formerly BMN 270) Clinical Program, a Gene Therapy for Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in a late breaking abstract session at the 59th American Society of Hematology (ASH) Annual Meeting &...
-
Nov 27, 2017
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into a definitive agreement to sell the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained in April of...
-
Oct 31, 2017- Credit Suisse's 26th Annual Healthcare Conference on November 7 in Scottsdale, AZ
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in Credit Suisse's 26th Annual Healthcare Conference on November 7, 2017 at 9:10am MT/11:10am ET, in...
-
Oct 26, 2017- Company Announces Total Revenues of $334.1 million in the Third Quarter of 2017; Full-year Revenue Guidance Confirmed at between $1.29 billion and $1.32 billion
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 % Change 2017 2016 % Change Total...
-
Oct 26, 2017Global Phase 3 Program to Begin Before Year End
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S. Food and Drug Administration (FDA) granted valoctocogene roxaparvovec (formerly BMN 270) Breakthrough Therapy Designation....
-
Oct 18, 2017Selection of BMN 290 Next IND Drug Development Candidate for Treatment of Friedreich's Ataxia
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) updated the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases....
-
Oct 18, 2017
BioMarin announced today that Brineura® (cerliponase alfa) has been awarded the 2017 Popular Science "Best of What's New" award in the health category. Each year, Popular Science reviews...
-
Oct 11, 2017
Key program updates will include the following: BMN 270 gene therapy for hemophilia A: 4e13 dose and Phase 3 Study Design Vosoritide for achondroplasia: long-term extension data Pegvaliase for...
-
Oct 10, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Oct 3, 2017
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Baxalta Chief Financial Officer and Chief...
-
Sep 14, 2017Regulatory Review Process Proceeding In-line with Company's Expectations
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has provided the company with the "Day-74" filing communication for its Biologics...
-
Sep 6, 2017Preliminary biomarker and liver size data show marked decreases; early cognitive effects encouraging, pending more mature data
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it presented interim data from the dose escalation arm of a Phase 1/2 trial for BMN 250, an investigational enzyme replacement...
-
Sep 5, 2017
BioMarin (Nasdaq:BMRN) announced that the company will present data in three platform presentations and fifteen poster presentations at the 13th International Congress of Inborn Errors of...
-
Aug 29, 2017
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for pegvaliase,...
-
Aug 23, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the underwriters of its recently announced public offering of 0.599% senior subordinated convertible notes due 2024 (the Notes)...
-
Aug 21, 2017For the fourth consecutive year, BioMarin ranks in top 20 on list
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has been ranked 12th on Forbes magazine's 2017 list of the "World's Most Innovative Companies." BioMarin, a pharmaceutical...
-
Aug 15, 2017- Citi's 12th Annual Biotech Conference on September 6 in Boston
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in Citi's Annual Biotech Conference on September 6, 2017 in Boston, Baird's 2017 Global Healthcare...
-
Aug 7, 2017BioMarin Announces Offering of $450 Million of 0.599% Senior Subordinated Convertible Notes Due 2024
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), announced today an underwritten offering of $450 million aggregate principal amount of 0.599% senior subordinated convertible notes due 2024 (the...
-
Aug 7, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), announced today an underwritten offering of $450 million aggregate principal amount of senior subordinated convertible notes due 2024 (the Notes)....
-
Aug 2, 2017- Company Announces Record Total BioMarin Revenues of $317.4 million in the Second Quarter of 2017
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2017 2016 % Change 2017 2016 % Change Total BioMarin Revenues
-
Aug 2, 2017- Recent 4e13 vg/kg Data Indicates Majority of Patients in Open-Label Phase 1/2 Study Expected to Achieve Factor VIII Activity Levels in the Normal Range
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it will expand its development plan for BMN 270, its investigational gene therapy for hemophilia A, to include an additional Phase...
-
Jul 31, 2017- Company to Also Provide Data and Development Plan Update on 4e13 vg/kg Dose of Investigational Gene Therapy Product BMN 270 for Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...
-
Jul 18, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...
-
Jul 18, 2017-- Agreement terms resolve global patent proceedings regarding Sarepta’s sale of EXONDYS 51® (etep-lirsen) and future Duchenne muscular dystrophy (DMD) exon-skipping products --
CAMBRIDGE, Mass. and SAN RAFAEL, Calif., July 18, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of...
-
Jul 11, 2017
BioMarin Provides BMN 270 Data at International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress Initiation of Phase 3 Registrational Study Planned for Q4 2017 with 6e13 vg/kg Dose 97%...
-
Jun 30, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that the company submitted a Biologics License Application (BLA) on Friday, June 30, 2017 to the U.S. Food and Drug Administration (FDA) for...
-
Jun 16, 2017Oral Presentation to Include Interim Results from its Ongoing Phase 1/2 BMN 270 Clinical Program, a Gene Therapy for Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in a late breaking abstract session at the International Society on Thrombosis and Haemostasis (ISTH)...
-
Jun 1, 2017Dosing includes all ages from birth for this fatal and rapid pediatric neurodegenerative condition
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the European Commission (EC) has granted marketing authorization for Brineura™ (cerliponase alfa), the first treatment approved in the...
-
May 31, 2017- Goldman Sachs 38th Annual Global Healthcare Conference on June 13 in Rancho Palos Verdes, CA
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will participate in the Goldman Sachs 38th Annual Global...
-
May 4, 2017- First Quarter 2017 Total BioMarin Revenues Increase 28% Year over Year to $304 million
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2017 2016 % Change Total BioMarin Revenues $ 304 $ 237 28 % Aldurazyme Net Product...
-
May 2, 2017- Deutsche Bank's 42nd Annual Health Care Conference on May 3 in Boston
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in Deutsche Bank's 42nd Annual Health Care...
-
Apr 27, 2017Brineura™ is the first FDA-approved treatment for this fatal neurodegenerative condition
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) approved Brineura™ (cerliponase alfa) to slow the loss of ambulation in symptomatic...
-
Apr 21, 2017One of the First Therapies to Receive Positive CHMP Opinion Using New Accelerated Assessment Process
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has...
-
Apr 20, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May...
-
Apr 13, 2017Retains exclusive U.S. rights until October 1, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that it has entered into a settlement agreement with Par Pharmaceutical that resolves patent litigation in the United States (U.S.)...
-
Feb 23, 2017- Full Year 2016 Total BioMarin Revenues Increase 26% Year over Year to $1.12 billion
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2016 2015 % Change 2016 2015 % Change Total...
-
Feb 15, 2017Oral Presentations to Include Research and Data in Ongoing Studies for the Treatment of Morquio A Syndrome and CLN2 Disease, a Form of Batten Disease
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in four oral and seven poster presentations at the 13th Annual WORLDSymposium™ being held February...
-
Feb 8, 2017- Leerink Partners 6th Annual Global Healthcare Conference on February 16 in New York City
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the Leerink Partners 6th Annual Global...
-
Feb 7, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Feb 1, 2017First Product to be Eligible for Access to PRIME in Hemophilia
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) regulatory initiative for the company's...
-
Jan 8, 2017Factor VIII Levels Maintained for All High Dose Patients at 34-50 Weeks
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today an update to its positive interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for...
-
Jan 3, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 35th Annual J.P. Morgan Healthcare Conference on
-
Dec 12, 2016
SAN RAFAEL, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has initiated a global Phase 3 study for vosoritide, an analog of...
-
Nov 3, 2016Credit Suisse 25th Annual Healthcare Conference on November 7 in Scottsdale, Arizona
SAN RAFAEL, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will...
-
Oct 27, 2016Third Quarter 2016 Total BioMarin Revenues Increase 34% Year over Year to $280 million
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 % Change 2016 2015 % Change Total...
-
Oct 19, 2016Highest Dose (30 µg/kg/day) Shows Approximately 50% Increase in Mean Annualized Growth Velocity, Comparable with 15 µg/kg/day dose
SAN RAFAEL, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today provided an update on its Phase 2 study of vosoritide, an analog of C-type Natriuretic...
-
Oct 13, 2016Phase 1/2 Study Expected to Resume by End of 2016
SAN RAFAEL, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United...
-
Oct 11, 2016
SAN RAFAEL, Calif., Oct. 11, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...
-
Sep 21, 2016BioMarin to Seek Review of Ruling in Composition of Matter Patent Interference (No. 106,008)
SAN RAFAEL, Calif., Sept. 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it intends to seek a review of the Patent Trial and Appeal Board (PTAB) of...
-
Sep 14, 2016CHMP Opinion and EU Decision Expected Q3 2017
SAN RAFAEL, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the European Medicines Agency (EMA) validated the Marketing Authorization...
-
Sep 8, 2016Oral Presentations Include Updated Long-Term Data from Extension Study of Brineura™ (Cerliponase Alfa) in Children with CLN2 Disease, and Long-Term Safety and Efficacy Data of Pegvaliase in Adults with PKU
SAN RAFAEL, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that two oral and 16 poster presentations related to the company's products and...
-
Sep 6, 2016Additional Data Submitted to BLA following FDA Request, PDUFA Action Date Extended to April 27, 2017
SAN RAFAEL, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced a program update for cerliponase alfa, a recombinant human tripeptidyl peptidase 1...
-
Aug 31, 2016Citi's 11th Annual Biotech Conference September 7 in Boston
SAN RAFAEL, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that management will participate in the Gene Therapy Panel at Citi's 11th Annual...
-
Aug 24, 2016For the third consecutive year, BioMarin ranks in top 10 on list
SAN RAFAEL, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has been ranked 10th on Forbes magazine's 2016 list of the "World's Most...
-
Aug 9, 2016
SAN RAFAEL, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing of an underwritten public offering of 7,500,000 shares of its common...
-
Aug 8, 2016
SAN RAFAEL, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 7,500,000 shares of its...
-
Aug 4, 2016Second Quarter 2016 Total BioMarin Revenue Increases 20.0% Y/Y to $300.1 million
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2016 2015 % Change 2016 2015 % Change Total BioMarin Revenue
-
Jul 27, 2016Potential First Treatment for Fatal, Rare, Brain Disease in Children
SAN RAFAEL, Calif., July 27, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the submission...
-
Jul 27, 20166 of 7 High Dose Patients Show Factor VIII levels above 50%, 7th patient above 10%
SAN RAFAEL, Calif., July 27, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today positive interim results of an open-label Phase 1/2 study of BMN 270, an...
-
Jul 21, 2016Conference call and web-cast to be held Wednesday, July 27th at 4:05pm ET
SAN RAFAEL, Calif., July 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that interim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII...
-
Jul 18, 2016
SAN RAFAEL, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment...
-
Jul 14, 2016
SAN RAFAEL, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...
-
Jun 20, 2016Investor event to be held in Orlando following the July 27 oral presentation at the WFH meeting
SAN RAFAEL, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the upcoming oral presentation summarizing a late breaking abstract accepted for...
-
May 31, 2016
SAN RAFAEL, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has withdrawn its Kyndrisa™ (drisapersen) Marketing Authorization...
-
May 4, 2016Bank of America Merrill Lynch 2016 Health Care Conference on May 11 in Las Vegas
SAN RAFAEL, Calif., May 04, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate...
-
May 3, 2016EU and U.S. Marketing Application Submissions Planned for Mid-Year 2016
SAN RAFAEL, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the European Medicines Agency (EMA) has granted BioMarin's request for...
-
Apr 28, 2016First Quarter 2016 Total BioMarin Revenue Increases 16.7% Y/Y to $236.7 million
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2016 2015 % Change Total BioMarin Revenue $ 236.7 $ 202.9 16.7 % Vimizim Net...
-
Apr 21, 2016European Commission Grants BMN 250 Orphan Drug Designation to Treat Ultra-Rare Condition
SAN RAFAEL, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has enrolled the first patient in a Phase 1/2 trial for BMN 250, an...
-
Apr 20, 2016Two High Dose Patients Show Increasing Levels of Factor VIII Above 50%
SAN RAFAEL, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today preliminary data from an ongoing Phase 1/2 clinical trial with BMN 270, an...
-
Apr 20, 2016New Data Shows Durable and Consistent Effects on Mean Annualized Growth Velocity for up to 12 months with Increases of 46%-65% from Baseline
SAN RAFAEL, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today provided an update on its Phase 2 study of vosoritide, an analog of C-type Natriuretic...
-
Apr 18, 2016Key development updates will include preliminary data with BMN 270, gene therapy for hemophilia A, and one year data with vosoritide for achondroplasia
SAN RAFAEL, Calif., April 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will host an R&D Day from 8am (ET) to 12pm (ET) on Wednesday, April 20, 2016 in New York City....
-
Apr 12, 2016
SAN RAFAEL, Calif., April 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin,...
-
Mar 24, 2016
SAN RAFAEL, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BMN 270, an investigational gene therapy for the treatment of hemophilia A,...
-
Mar 21, 2016In 8-week Placebo-Controlled Portion No Benefit in Inattention or Mood Scores Were Observed
SAN RAFAEL, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- BioMarin announced today that the pivotal Phase 3 PRISM-2 study (formerly referred to as 165-302) of pegvaliase met the primary endpoint of...
-
Mar 3, 2016Cowen and Company 36th Annual Health Care Conference on March 8 in Boston
SAN RAFAEL, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will...
-
Mar 2, 201680% Reduction in Clinical Disease Progression in One Year Compared to Natural History (p <0.0001)
SAN RAFAEL, Calif., March 02, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced positive 48-week results from its Phase 1/2 pivotal study for cerliponase alfa, a...
-
Mar 1, 2016
SAN RAFAEL, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BMN 270, an investigational gene therapy for the treatment of patients with...
-
Feb 29, 2016Oral Presentations Include Results From Phase 1/2 Study on Cerliponase Alfa in Children With CLN2 Disease, a Form of Batten Disease
SAN RAFAEL, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company will present data in six oral and 15 poster presentations at the 12th
-
Feb 29, 2016On Rare Disease Day, BioMarin Highlights Its Commitment to Patients With Morquio A, MPS VI and Phenylketonuria (PKU) and Their Caregivers With Personalized Resources
SAN RAFAEL, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the launch of BioMarin RareConnectionsTM, rebranding its patient-focused offering...
-
Feb 25, 2016Full-year 2015 Total BioMarin Revenue Increases 18.8% to $889.9 million Year-over-Year
Financial Highlights ($ in millions, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2015 2014 % Change 2015 2014 % Change Total BioMarin Revenue...
-
Jan 28, 2016
SAN RAFAEL, Calif., Jan. 28, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...
-
Jan 14, 2016Marketing Application in Europe Remains Under Review
SAN RAFAEL, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter...
-
Jan 11, 2016Reveglucosidase Alfa Trends Positive in Respiratory Muscle Strength and Endurance Endpoints in Patients Previously Treated With Enzyme Replacement Therapy
SAN RAFAEL, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced interim results from INSPIRE, a Phase 2 trial for reveglucosidase alfa, a fusion...
-
Jan 5, 2016
SAN RAFAEL, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will...
-
Jan 4, 2016
SAN RAFAEL, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that David Pyott has been elected to the company's board of directors. Mr. Pyott is...
-
Dec 18, 2015
SAN RAFAEL, Calif., Dec. 18, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that they...
-
Nov 24, 2015
SAN RAFAEL, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that NASDAQ has halted trading of the company's stock. The Peripheral and Central...
-
Nov 24, 2015
SAN RAFAEL, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Company's presentation from the Peripheral and Central Nervous System...
-
Nov 24, 2015If Approved, Kyndrisa Would Become the First Disease-Modifying Therapy for Patients With Duchenne Muscular Dystrophy in the United States Amenable to Exon 51 Skipping
SAN RAFAEL, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S....
-
Nov 23, 2015Recommendation Provides Patient Access to Treatment for Ultra-Rare Condition With Reimbursement
SAN RAFAEL, Calif., Nov. 23, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the The National Institute for Health and Care Excellence (NICE), NHS England...
-
Nov 20, 2015
SAN RAFAEL, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the U.S. Food and Drug Administration (FDA) posted briefing materials prepared...
